Havens Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Havens Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-143,266	Closed	-$6.88M	–	34
2020 Q1	$6.88M	Buy	143,266 +27,266	+24%	+$1.27M	6.71%	7
2019 Q4	$5.44M	Buy	+116,000	New	+$5.13M	4.77%	8

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Havens Advisors's RARX Position: Q2 2020 in Review

Havens Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 143,266 shares — an estimated $6.88M sold.

Havens Advisors first reported a position in RARX in Q4 2019 and held it in 2 quarters. The position peaked at $6.88M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Havens Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Havens Advisors sold 143,266 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $6.88M.
Havens Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Havens Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $6.88M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Havens Advisors's 13F filing for Q2 2020, filed 24 Jul 2020.